ZY19489

Zydus Cadila

Product vision
  • Uncomplicated malaria treatment and resistance management
MoA
  • Unknown 

Key features
  • Predicted human dose 900mg for a 9-log parasite killing
  • Low resistance potential from in vitro studies
Challenges
  • Synthesis and cost of goods

Status
  • First-in-human study started in February 2019

Next milestone
  • Initiate phase IIb study of ZY19489 with FQ
Previously
  • Discovery partnership between MMV and AstraZeneca, Bangalore
  • Name AZ13721412; full reference name is MMV674253
MMV Project Director
  • Illaria Di Resta